The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions also addressed supply-demand challenges amid rising country demand and the potential role of newer vaccines like Cecolin. Preliminary data from the Philippines on HPV genotype distribution emphasized the need for local surveillance to inform tailored immunization strategies.